

# EVALUATION OF PORTAL VEIN THROMBOSIS IN LIVER GRAFT TEN YEARS AFTER LIVER TRANSPLANTATION DUE TO BUDD–CHIARI SYNDROME USING DOPPLER ULTRASOUND

Azra Husic-Selimovic<sup>1</sup>, Srdjan Gornjakovic<sup>1</sup>, Marcus Schuchmann<sup>2</sup>, Zora Vukobrat-Bijedic<sup>1</sup>,  
Gastroenterohepatology Department, Clinical center of University of Sarajevo, Sarajevo, Bosnia and Herzegovina<sup>1</sup>  
Klinik end Poliklinik Lagenbeckstrasse Mainz, Germany<sup>2</sup>

Corresponding author: Azra Husic-Selimovic, MD, PhD, Gastroenterohepatology Department. Clinical center of University of Sarajevo, Bolnicka 25, 71 000 Bosnia and Herzegovina. Tel. +38733667817. E-mail: husic\_azra@yahoo.com.

## Case report

### ABSTRACT

Budd-Chiari syndrome is a rare but life-threatening disorder characterized by obstruction of the hepatic venous outflow. Treatment depends

on underlying cause, extent of the obstruction and functional capacity of the liver. When all other therapy options are unsuccessful, liver transplant should be considered. Portal vein thrombosis (PVT) is a frequent event

in patients with cirrhosis which can be treated with anticoagulants, but there are limited data regarding safety and efficacy of this approach.

**Key words:** portal vein thrombosis, liver transplantation, Budd-Chiari Syndrome.

## 1. INTRODUCTION

Budd-Chiari syndrome is a rare but life-threatening disorder characterized by obstruction of the hepatic venous outflow. Treatment depends on underlying cause, extent of the obstruction and functional capacity of the liver. When all other therapy options are unsuccessful, liver transplant should be considered (1, 2, 3).

Portal vein thrombosis (PVT) is a frequent event in patients with cirrhosis which can be treated with anticoagulants, but there are limited data regarding safety and efficacy of this approach.

## 2. CASE REPORT

We present case report of thirty five old female patient with postparthal Budd-Chiari syndrome who underwent liver transplant on 2002, and developed portal vein thrombosis in liver graft ten years later. We also evaluated safety of application of anticoagulant therapy in this patients.

In few years after liver transplantation patient developed fibrosis of liv-

er graft with porthal hypertension. Thrombosis was diagnosed and recanalization was evaluated by using Doppler ultrasound. (Figure 1.) We performed elective esophageal variceal band ligation in order to prevent bleeding. As soon as we prevented possible complications, anticoagulant therapy (martefarin) was admin-

istred. (Figure 2.)

Complete recanalization of portal vein was achieved after four months period. Early initiation of anticoagulation was associated with complete recanalization. Our case suggested that appropriate and well prepared anticoagulant therapy in portal vein thrombosis of liver graft could pro-





Figure 1. Trombus in perihilar part of portal vein



**Figure 2.** Normal portal blood flow with complete (14x20 mm) and in parenchymal part ( 9x19 mm). recanalisation after four months

longe „life time“ of graft.

Anticoagulation is a relatively safe treatment that leads to partial or com-

plete recanalization of the portal venous of patients with cirrhosis and PVT. It could be maintained for longer

period to prevent rethrombosis.

**Conflict of interest:** none declared

**REFERENCES**

1. Huard G, Bilodeau M. Management of Anticoagulation for Portal Vein Thrombosis in Individuals with Cirrhosis: A Systematic Review. *Int J Hepatology*. 2012; 2012: 672986. Epub 2012 Jun 20.
2. Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. *Liver Int*. 2012 Jun 27. doi: 10.1111/j.1478-3231.2012.02839.
3. Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Optimal length of anticoagulant therapy in cirrhotic patients with portal vein thrombosis. *Liver Int*. 2012 Jun 27. doi: 10.1111/j.1478-3231.2012.02839

COPE

COMMITTEE ON PUBLICATION ETHICS

[Sign in](#)

Home
About COPE
Resources
Cases
Become a member
Members
Events
News & Opinion
Contact Us

## Promoting integrity in research publication

COPE is a forum for editors and publishers of peer-reviewed journals to discuss all aspects of publication ethics. It also advises editors on how to handle cases of research and publication misconduct. Read more [About COPE...](#)

### 1,2,3,4,5 Guidelines

Access COPE's official guidance, including the Retraction Guidelines.

### Flowcharts

Our flowcharts are designed to help editors follow COPE's Code of Conduct and implement its advice when faced with cases of suspected misconduct.

### eLearning

COPE's eLearning course is now live. Designed to give editors a deeper understanding about publication ethics and practical guidance about how to detect, prevent and handle misconduct.

### Code of Conduct

COPE aims to define best practice in the ethics of scholarly publishing and to assist editors, editorial board members, owners of journals and publishers to achieve this.

#### LATEST NEWS

### COPE North American Seminar and Forum 2012

COPE is pleased to announce its 4th North American Seminar and Forum, which will be held at the Bechtel Conference Centre, the home of the American Society of Civil Engineers, in Reston, Virginia, less than 10 miles from Dulles Airport, Washington, D.C. The COPE Forum will take place on the afternoon of 18 October (2–5 pm) followed by a whole day Seminar on 19 October.

[View details](#)

#### NEWS & OPINION

### News / COPE Flowcharts now available in Persian

3/8/2012 12.13pm

14 of the 17 COPE flowcharts are now available in Persian. The remaining three (fabricated data in a submitted manuscript, fabricated data in a published manuscript, and how COPE deals with complaints against member journals) will be available shortly. The Persian flowcharts join the Italian, Spanish, French and Chinese versions already available. Korean, Japanese, Turkish and Croatian will be coming soon. They can be accessed here: <http://publicationethics.org/resources/flowcharts>

### Opinion / Scientific misconduct being taken more seriously globally?

2/8/2012 8.03am by Natalie Ridgeway

*Nature* discusses how scientific misconduct is now starting to be taken much more seriously worldwide. The article states how different countries are starting to strengthen their response to scientific misconduct and that research integrity is now very much in the world's spotlight. The UK has a [voluntary] concordat for which universities have agreed to adopt, obliging them to investigate allegations of misconduct. A study in the US, due in 2013, is likely to call for changes in how misconduct is defined and policed by US agencies.

ACTA INFORM MED. 2012 SEP; 20(3): 194-195 / CASE REPORT